Sialylation of 3-Methylcholanthrene–Induced Fibrosarcoma Determines Antitumor Immune Responses during Immunoediting

Merav Cohen, Moshe Elkabets, Michal Perlmutter, Angel Porgador, Elena Voronov, Ron N. Apte and Rachel G. Lichtenstein

_J Immunol_ 2010; 185:5869-5878; Prepublished online 18 October 2010;
doi: 10.4049/jimmunol.1001635
http://www.jimmunol.org/content/185/10/5869

Supplementary Material  http://www.jimmunol.org/content/suppl/2010/10/19/jimmunol.1001635.DC1

Why _The JI_?

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

*average

References  This article _cites 50 articles_, 15 of which you can access for free at: http://www.jimmunol.org/content/185/10/5869.full#ref-list-1

Subscription  Information about subscribing to _The Journal of Immunology_ is online at: http://jimmunol.org/subscription

Permissions  Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts  Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Sialylation of 3-Methylcholanthrene–Induced Fibrosarcoma Determines Antitumor Immune Responses during Immunoediting

Merav Cohen,*1 Moshe Elkabets,†1 Michal Perlmutter,*, Angel Porgador,† Elena Voronov,† Ron N. Apte,‡ and Rachel G. Lichtenstein*‡

Sialylation of tumor cells is involved in various aspects of their malignancy (proliferation, motility, invasion, and metastasis); however, its effect on the process of immunoediting that affects tumor cell immunogenicity has not been studied. We have shown that in mice with impaired immunoediting, such as in IL-1α+/− and IFNγ−/− mice, 3-methylcholanthrene–induced fibrosarcoma cells are immunogenic and concomitantly bear low levels of surface sialylation, whereas tumor cells derived from wild type mice are nonimmunogenic and bear higher levels of surface sialylation. To study immune mechanisms whose interaction with tumor cells involves surface sialic acid residues, we used highly sialylated 3-methylcholanthrene–induced nonimmunogenic fibrosarcoma cell lines from wild type mice, which were treated with sialidase to mimic immunogenic tumor cell variants. In vivo and in vitro experiments revealed that desialylation of tumor cells reduced their growth and induced cytotoxicity by NK cells. Moreover, sialidase-treated tumor cells better activated NK cells for IFN-γ secretion. The NKG2D-activating receptor on NK cells was shown to be involved in interactions with desialylated ligands on tumor cells, the nature of which is still not known. Thus, the degree of sialylation on tumor cells, which is selected during the process of immunoediting, has possibly evolved as an important mechanism of tumor cells with low intrinsic immunogenicity or select for tumor cells that can evade the immune system or subvert its function. When immunoediting is impaired, such as in IFN-γ−/− and IL-1α−/− mice, the overt tumor consists of desialylated tumor cells that interact better with immunosurveillance cells.

Sialic acid, an acidic sugar at physiologic conditions that is found mainly at the outer ends of cell surface glycan chains, is elevated and frequently varied in glycan epitopes. In the malignant process, the presence of sialic acid is correlated with tumor cell proliferation, cell motility, invasion, metastasis, and poor prognosis (1–5). Studies addressing the effects of sialic acid on either tumor cell lipids or glycoproteins in modulating tumor-immune responses have shown that sialic acids can prevent cell–cell interactions, through nonspecific charge repulsion effects (6), participate in engagement of immune cell adhesion molecules such as the Ig-like lectin receptors (siglec) (7, 8), and mask the underlying glycan structure, thus avoiding recognition by other lectins such as galectins and C-type lectins (9–11). Although the effects of sialylated tumor glycomolecules on immune responses have been examined (6–11), there is no information on levels of surface sialylation of selected tumor cells during tumor immunoediting and creating the immunogenic repertoire of malignant cells during tumorigenesis.

Several studies have experimentally proved the concept of immunoediting, in which immune responses of the host during tumorigenesis select tumor cell variants lacking stress ligands. Ags essential for immune recognition by immune effector cells, or tumor cells that can evade the immune system or subvert it (12–15). The immunoediting concept evolved from observations that tumors arising in immunodeficient mice present an immunogenic phenotype (16, 17). We have shown previously that tumors induced by the carcinogen 3-methylcholanthrene (MCA) in IL-1α−/− mice were not properly edited and were thus highly immunogenic and nontumorigenic in intact mice, as compared with MCA-induced fibrosarcoma cells derived from wild type (WT) BALB/c mice (18). Surface sialylation levels and expression patterns of α2-6 sialyltransferase were lower in cell lines derived from IL-1α−/− mice than in cell lines derived from WT mice (19). This finding was also shown to be valid for cell lines derived from MCA-induced fibrosarcoma cells from IFN-γ−/− mice, because IFN-γ is a key component of the cancer immunoediting process (20). Because these immunodeficient cell lines bear low sialylation levels, we hypothesized that there is selection for tumor cell variants enriched in surface sialylation when immunoediting is intact. Variants arising from impaired immunoediting contain less sialylated surface glycoconjugates, which enables them to be immunogenic and less tumorigenic. Previously, we and others have also shown that innate immunosurveillance cells, especially NK cells, are involved in eradicating immunogenic tumor cell variants during the process of immunoediting both in IL-1α−/− and IFN-γ−/− mice, which subsequently shapes the immunogenic repertoire of the malignant cells (18, 20). NK cells play a major role in tumor immunosurveillance.

*Department of Biotechnology Engineering, Faculty of Engineering; and †Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences and National Institute of Biotechnology, Ben-Gurion University of the Negev, Beer-Sheva, Israel
‡Department of Biotechnology Engineering, Faculty of Engineering, and †Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences and National Institute of Biotechnology, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Received for publication May 18, 2010. Accepted for publication September 17, 2010.

This work was supported by the Israel Glycobiology Center at Ben-Gurion University. R.G.L. is supported by the European Union Sixth Research Framework Programme (FP6). M.E. is supported by the International Sephardic Education Foundation and a Nehemia-Lev-Zion scholarship.

Address correspondence and reprint requests to Rachel G. Lichtenstein, Department of Biotechnology Engineering, Faculty of Engineering, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel. E-mail address: ruha@bgu.ac.il

The online version of this article contains supplemental material.

Abbreviations used in this paper: FSG, fish gelatin; i.e.p., intrafootpad; MCA, 3-methylcholanthrene; MFI, mean fluorescence intensity; SNA, sambucus nigra lectin; TAg, Galβ(1,3)GalNAcα-1; Tn-Ag, GalNAcα-1; WT, wild type.

Copyright © 2010 by The American Association of Immunologists, Inc. 0022-1767/10/$16.00
by serving as the first line of antitumor immune defense (21). The antitumor activity of NK cells is determined by a balance between stimulatory and inhibitory receptor signals, such as NKG2D and MHC class I molecules, respectively (22, 23). The abundant NKG2D ligands expressed on tumor cells better engage the activating NKG2D receptor, thus promoting NK-derived IFN-γ production. IFN-γ can activate various types of innate and adaptive immune mechanisms and enhance tumor cell lysis (24–26).

In this study, we have used an experimental model consisting of sialidase-treated cells derived from MCA-treated WT mice to assess the involvement of sialic acid residues in interactions of tumor cells with the host immune system. In a set of in vivo and in vitro experiments, we illustrate that the treated fibrosarcoma cells increased their immunogenic capacity and interactions with the host NK cells. Our in vivo experiments clearly show the involvement of NK cells in growth inhibition and lysis of sialylated tumor cells. Our studies revealed a correlation between sialic acid expression levels on tumor cells, NKG2D ligand receptor engagement, and NK cell cytotoxic activity. NKG2D was found to be crucial in low-sialylated tumor cell lysis. The therapeutic potential of the results is discussed below.

Materials and Methods

Mice

Female BALB/c mice (6–14 wk old) were purchased from Harlan Breeders (Livermore, CA), and IFN-γ knockout mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The generation of IL-1α−/− mice was described previously (27). These mice were backcrossed with BALB/c mice for more than eight generations and were homozygous for the relevant mutation. The mice were bred and kept at the Animal Facilities of the Faculty of Health Sciences, Ben-Gurion University, under aseptic conditions. Mice were treated according to the National Institutes of Health Animal Care guidelines adopted by the Ben-Gurion University Committee for the Ethical Care and Use of Animals in Research.

Cell lines and primary fibroblasts

Fibrosarcoma cell lines were generated by injection of MCA (Sigma-Aldrich, St. Louis, MO), as previously described (28). Primary fibroblasts were produced from the dorsal skin of BALB/c and IL-1α−/− mice, as described previously (29). The cells were grown in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2 mM L-glutamine, in a humidified 5% CO2 atmosphere at 37°C. All medium ingredients were purchased from Biological Industries (Bet-Haemek, Israel).

Sialidase treatment and kinetic analysis of sialic acid recovery

For external reduction of terminal sialic acids, 6 × 106 cells were treated with 10 μM sialidase A (ProZyme, San Leandro, CA). Treatment was performed in 100 μl sodium-phosphate buffer (pH 6) for 10, 30, 45, and 60 min at 37°C. For kinetic analysis of the recovery of sialic acid residues after 1 h of treatment, 5 × 103 sialidase-treated cells were recultured in six-well plates in 2 ml medium. Cells were then harvested by trypsin-EDTA treatment at different points over 48 h. After multiple washes with PBS, the cells were fluorescently labeled with sambucus nigra lectin (SNA)-FITC lectin (Vector Laboratories, Burlingame, CA) for determination of α2-6 sialic acid levels by FACS. Recovery was calculated as the sialic acid level detected at a specific time, relative to the sialic acid level of fluorescently marked untreated cells of the same type (i.e., the basal level). Tumor cells treated for 1 h with sialidase were used in all experiments, except those showing the effects of gradient sialic acid levels.

Proliferation, apoptosis, and soft agar colony formation

For proliferation analysis, 5 × 103 cells were seeded in 96-well plates in a volume of 200 μl and assessed by an assay based on WST-1 reagent (Roche, Mannheim, Germany), following the manufacturer’s instructions. An apoptosis assay using an annexin V kit (Bender MedSystems, Burlingame, CA) was performed on 5 × 104 cells before and after sialidase treatment, followed by FACS analysis. Soft agar colony formation using sialidase-treated and untreated cells was assessed as described previously (30).

Fluorescence microscopy

Cells (1 × 105) were fixed in 4% formaldehyde in PBS for 15 min at room temperature, washed with PBS, and blocked with 1% fish gelatin (FGS) in PBS-Tween solution for an additional 30 min. Next, FITC-labeled SNA lectin (2.5 ng per sample) in PBS containing 0.2% FSG was added for 1 h at room temperature and then washed three times. Fluorescent staining of actin filaments was observed following labeling by (1:500) Oregon Green 488 phalloidin (Invitrogen) in PBS containing 0.2% FSG. For nuclear staining, (1:1000) Hoechst dye (Invitrogen) in PBS containing 0.2% FSG was added. Finally, all cover slips were placed on slides containing 50% glycerol and inspected with an inverted microscope equipped with an Olympus IX81 camera, using appropriate fluorescent filters (Olympus, Center Valley, PA).

Invasiveness of 3-MCA–induced cell lines

For determining tumorigenicity patterns of sialidase-treated and untreated MCA-induced fibrosarcoma cells, 1 × 106 cells were suspended in 50 μl PBS and injected intrafootpad (i.p.) in control or irradiated BALB/c mice (5 Gy of γ-Cobalt 60 per mouse; i.e., 600 rad). Local tumor growth was determined every 2–3 d by caliper measurement of tumor diameter.

Metastasis of MCA-induced cell lines

For determining lung metastasis, sialidase-treated and untreated cells (1 × 106) were suspended in 200 μl PBS and injected i.v. into the tail vein of mice. Two weeks later, mice were sacrificed and their lungs were weighed and photographed with a digital camera. Mouse survival was determined daily during the 40 d after i.v. injection.

Spleen cell isolation and NK cell enrichment

Spleen cells derived from mice were cultured in 24-well plates at a concentration of 1 × 106 cells per well. Splenic NK cells were enriched using a negative selection kit, according to the manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). NK cell enrichment was verified by FACS analysis. Approximately 75–90% of the recovered cells were CD3− DX5+ CD122+.

Coculturing of tumors with immune cells and NKG2D ligand blocking

MCA-induced fibrosarcoma cells treated with mitomycin-C (Sigma-Aldrich; 100 μg/106 cells treated for 1 h at 37°C) were added to naive spleen or enriched NK cells, as described previously (24). Cocultures were incubated in RPMI 1640 medium (Invitrogen) supplemented with 10% FCS, 2 mM L-glutamine, 100 μM penicillin, 0.1 mg/ml streptomycin, and 100 μg/ml IL-2. Coculture supernatants were collected 24 h after seeding, and cytokine amounts in the culture supernatants were measured by ELISA. To quantify secreted IFN-γ in cocultures with a blocked NKG2D receptor, 1 × 106 enriched NK cells were preblocked with 0.5 μg anti-NKG2D/CD134 Abs (eBioscience, San Diego, CA) in a volume of 100 μl for 30 min at 4°C. The treated NK cells were cocultured with sialidase-treated or untreated cells after supernatant collection and cytokine assessment by ELISA.

Intracellular staining

For intracellular IFN-γ detection, cocultures were supplemented with 100 ng/ml IL-12, followed by Golgi-stop treatment (BD Biosciences, San Jose, CA) using a diluted stock solution of 1:1000 12 h later, and stained using a Cytofix/Cytoperm kit according to the manufacturer’s instructions (BD Pharmingen, San Diego, CA). The cells were finally stained with NK cell markers and anti–IFN-γ Abs and subsequently quantified by FACS analysis.

NKG2D-Ig ligand binding

For detection of NKG2D ligands by flow cytometry, cell lines were stained with an mNKG2D-fusion protein (mNKG2D-FP) (31). For kinetic measurements of NKG2D ligand–receptor interactions, 6 × 105 untreated fibrosarcoma cells were preincubated with 10 μM sialidase every 10 min for 1 h. The treated cells were washed with PBS and then incubated with mNKG2D receptor-fusion protein (mNKG2D), as described previously (30).

In vivo depletion of lymphoid cell subpopulations

In vivo depletion of CD4+ and CD8+ T cells was achieved via multiple i.p. injections of ascitic fluids containing the relevant monoclonal Abs—GK1.5 and YTS-169, respectively. Injection of Abs was performed on days
Flow cytometry

To detect surface α2-6 sialic acids on primary and tumor cells, skin fibroblasts and MCA-induced tumor cell lines were stained with FITC-labeled SNA lectin, as described previously (25). For detection of MHC class I and NKGD2 ligands, the cell lines were harvested and blocked with PBS plus 0.5% FBS and purified anti-CD16/CD32 Abs (Biolegend, San Diego, CA). Subsequently, the cells were stained with MHC class I-FITC–conjugated mouse anti–H-2Kd mAbs (clone SF1-1.1; BD Pharmingen) and mNKGD2-FP. Biotinylated donkey anti-human IgG antiserum (Jackson ImmunoResearch Laboratories, West Grove, PA) was used as a second-step reagent, followed by staining with PE-conjugated streptavidin (Jackson ImmunoResearch Laboratories).

Isolated spleen cells from BALB/c mice were stained for cell subsets by APC–PE–labeled anti-CD49b (clone DX5; Biolegend), anti-mouse CD122-PE (BD Biosciences), FITC–anti-mouse CD3ε (Biolegend), and ALEXA647–anti-mouse NKP46 (eBioscience) Abs.

Frozen and paraffin section analysis

Tumors were removed from the footpads or lungs of mice injected with sialidase-treated or untreated tumor cells. For paraffin sections, the tumors were immediately fixed and stained with H&E using an established protocol (27). For frozen sections, tumors were fixed and stained as described previously (32). Paraffin or frozen stained sections were viewed with light or confocal microscopes at ×20 and ×40 magnification, respectively.

Measurement of secreted cytokines

Murine IFN-γ, TNF-α, IL-2, IL-4, IL-6, and IL-12 levels were measured using a commercial ELISA kit (BD Pharmingen), according to the manufacturer’s instructions and as described previously (33).

Cytolytic assay

For in vitro and in vivo NK cell cytolytic activity assays, 200 μg of poly(I):poly(C) (Sigma-Aldrich) were injected into naive mice, and spleen cells were removed 18 h later (34). The cytolytic activity was evaluated in cocultures of target cells with the treated spleen cells in a 4+1 CFSE/7-AAD flow cytometry assay as described (35). For in vivo NK cell-killing assays (34), sialidase-treated cells were labeled with the fluorescent dye Vybrant DiD (Invitrogen), and untreated cells were labeled with the fluorescent dye Vybrant DiD (Invitrogen). Cells were mixed at a density of 2 × 10^7 cells of each population per milliliter of PBS, and 200 μl was injected into the tail vein. Lungs were collected after the injections or 5 h later, single-cell suspensions were obtained with cell strainers, and fluorescence was analyzed by flow cytometry. The ratio of treated target cells to untreated cells was calculated. For in vivo NK cell killing after NKGD2 blocking, mice were injected i.p. with 200 μg anti-NKG2D–CD134 Abs per mouse, 24 h before injection of sialidase-treated and untreated tumor cells.

Cell conjugation and confocal analysis

To evaluate the number of immune synapses formed by NK and target cells, poly(I):poly(C) activated NK cells were isolated from naive mice and conjugated to sialidase-treated or untreated fibrosarcoma cells at a ratio of 2:1 on poly-l-lysine–coated glass slide chambers (Sigma-Aldrich). Adherent cells were fixed, permeabilized, and washed using the Cytofix/Cytoperm kit (BD Biosciences). Staining NK and tumor cell conjugates with anti-mouse CD11a Abs (clone M17/4; Biolegend) was followed by staining with Alexa Fluor 633-conjugated anti-rat IgG (Invitrogen) for LFA-1 detection. To detect F-actin, cells were stained with Oregon green 488 phalloidin (Invitrogen). VECTASHIELD Mounting Medium (Vector Laboratories) with DAPI was subsequently added to stain nuclei and preserve fluorescent intensity. The cell conjugates were viewed in a Zeiss Laser Scanning Confocal Microscope (Goettingen, Germany). Each conjugate was scored for polarization of the activating synapse markers LFA-1 and F-actin, as described previously (36). Synapse formation percentages were calculated by dividing the number of conjugates showing polarization of activating synapse markers to the total number of conjugates.

Statistical analysis

Each experiment was repeated at least three times with similar response patterns. In experiments on the invasiveness of MCA-induced fibrosarcoma cell lines, experimental groups consisted of 5–10 mice. The data shown correspond to pooled or single representative experiments, as indicated, and are expressed as mean ± SD. Significant differences in results were determined using the two-sided Student t test, with p < 0.05 being considered significant.

Results

Surface sialylation levels of MCA fibrosarcomas derived from immunodeficient or BALB/c mice are slowly recovered after sialidase treatment

We first documented the natural level of sialic acids in MCA fibrosarcomas derived from WT mice. The sialic acid levels were compared with those isolated in immunogenic fibrosarcoma cell lines originating from IL-1α/−/− mice (19), as well as in primary fibroblasts, by fluorescence microscopy and flow cytometry using FITC-tagged SNA, which is able to bind α2-6 sialic acid. Whereas primary fibroblasts derived from WT and IL-1α/−/− mice showed similar staining with SNA (Fig. 1A), MCA-induced fibrosarcoma cell lines derived from IL-1α/−/− mice exhibited low staining and binding with SNA, as compared with fibrosarcoma cell lines derived from WT mice (Fig. 1A). These results coincide with flow cytometry evaluations of sialic acid levels in additional MCA-induced fibrosarcoma cell lines originated from IFN-γ/−/− mice in our laboratory (Fig. 1B). Mice lacking IFN-γ have been shown to bear increased susceptibility to MCA-induced sarcoma (20). As such, sarcoma immunogenicity in the second recipients was confirmed in our IFN-γ/−/− cell lines. As expected, IFN-γ/−/− cells injected i.p. developed tumors at a lower rate than did WT fibrosarcomas (Fig. 1B). Collectively, these results indicate that sialic acid surface expression is elevated during carcinogenesis and is associated with tumor immunoeediting.

Fibrosarcoma cell lines derived from WT mice were treated with sialidase A, which cleaves nonreducing terminal sialic acid in α2, α3, α6, α8, or α9 linkages and which are stained by SNA (Supplemental Fig. 1A). The renewal of sialic acid levels to the original status was examined in sialidase-treated WT and IL-1α/−/− fibrosarcoma cell lines. According to our previous study, MCA-induced fibrosarcoma cell lines derived from IL-1α/−/− mice express lower amounts of α2-6 sialyltransferase (ST6Gall) compared with fibrosarcoma cells derived from naive BALB/c mice (19). Therefore, the recovery of sialic acids on IL-1α/−/− tumor cells was also 50% lower than sialic acid recovery on fibrosarcoma cell lines derived from BALB/c mice at the same time (Supplemental Fig. 1B). Complete recovery of sialic acid levels was obtained after ~48 h, a period that allows in vivo examination of the immune response of the sialidase-treated tumor cells.

To verify that cellular competency was not impaired by the sialidase treatment, the rates of proliferation, the ratio of apoptosis, and the ability of the cells to form colonies on soft agar were assessed. No significant differences in proliferative ability, colony formation, or apoptotic ratios were observed between the sialidase-treated and untreated cells. These results indicate that sialidase-treated cells can be used as a model for studying the role of tumor cell sialylation in antitumor immunity in vivo (Fig. 1C).

Host response to sialidase-treated tumor cells results in tumor growth inhibition

We next studied the in vivo contribution of desialylated fibrosarcoma cells to tumor progression. Injection of sialidase-treated tumor cells into the footpads of syngenic mice resulted in an...
inhibition of tumor growth that lasted ~30–40 d after tumor cell injection, as compared with the rapid tumor growth rate observed with untreated cells (Fig. 2A). Similar injection of treated cells 0–60 min after sequential sialidase treatments resulted in a linear gradient of tumor growth inhibition (Supplemental Fig. 2A). In addition, i.v. injection of sialidase-treated cells into mice resulted in 100% survival, compared with the earlier death of mice injected with untreated cells (Fig. 2B). Lung analysis performed 2 wk after untreated cell injection showed significantly high metastasis formation, as indicated by lung weights in mice injected with untreated cells, relative to lungs from mice injected with treated cells (Fig. 2C). Next, sialidase-treated and untreated tumor cells were injected i.f.p. and i.v. into immunocompromised, sublethally irradiated mice. The sialidase-treated and untreated tumor cells induced the formation of solid tumors, leading to similar kinetics of mouse death (Fig. 2D). These results indicate that sialidase-treated cells are likely to be immunogenic and did not lose their invasive potential.

Histologic section analysis of the i.f.p. injection site showed greater accumulation and migration of infiltrate cells within the first day of sialidase-treated cell injection, as compared with what was seen with injection of untreated cells. Ten days later, a solid tumor was detected at the site injected with untreated cells. A much smaller tumor was observed when sialidase-treated cells were injected (Fig. 2E). In lungs, micrometastasis was observed 14 d after i.v. injection with sialidase-treated cells, as compared with the macrometastasis seen with untreated tumor cells (Fig. 2F). These observations indicate that the low levels of sialic acid on malignant cells resulted in tumor growth inhibition and enhanced leukocyte migration into the tumor microenvironment.

**NK cells are involved in tumor growth inhibition of sialidase-treated cells**

Identifying the lymphoid cell subsets involved in tumor inhibition of sialidase-treated cells was achieved by in vivo assessment of tumor growth in NK or T cell-depleted mice (Supplemental Fig. 2B). Depletion of CD4+ and CD8+ T cells resulted in similar kinetics of sialidase-treated tumor growth inhibition following i.f.p. injection, as observed in intact mice. By contrast, NK cell depletion had the most significant effects on the growth of sialidase-treated tumor cells, as compared with growth in intact mice (Fig. 3A). Lung weights were significantly elevated in NK-depleted mice that were injected i.v. with sialidase-treated, as compared with lung weights measured in CD4−/−depleted, CD8−/−depleted, or WT mice injected with treated cells (Fig. 3B).

Further evidence pointing to the NK cell involvement in tumor inhibition of sialidase-treated cells was observed by immunohistochemical examination of frozen sections. Analysis of the i.f.p. injection site revealed significant accumulation and migration of NK cells in the infiltrate cells within 2 d after sialidase-treated cell injection (Fig. 3C).

Finally, the number of synapses was evaluated by conjugating activated NK cells to sialidase-treated or untreated cells. Immune synapses were quantified by determining the polarization of LFA-1 and F-actin at the interface between the effector and target cells. Anti-CD11a (LFA-1) Abs stained integrin molecules that participate...
in the adhesion and stimulation of NK cells and their target cells. F-actin staining showed tight collars at the contact site owing to the accumulation of actin during formation of conjugates (Fig. 3D). There were 3-fold more immune synapses between NK cells and sialidase-treated cells compared with untreated cells. In some cases, a single NK cell was found to form simultaneous immune synapses with more than one sialidase-treated tumor cell. In contrast, fewer synapses were formed by highly sialylated tumor cells and NK cells. These data show the contribution of NK cells to sialidase-treated tumor cell inhibition in vivo and show the cytotoxic interactions between NK cells and sialidase-treated tumor cells in vitro.

Reduction of sialic acid levels triggers IFNγ secretion and NK cell cytotoxicity
To further investigate the nature of the immune response against sialidase-treated cells, immune-secreted cytokines were assessed in vitro. Coculturing of sialidase-treated tumor cells with naive...
FIGURE 3. NK cells are involved in tumor growth inhibition of sialidase-treated cells. Depletion of CD4, CD8, and NK cells in BALB/c mice was achieved by multiple i.p. injections of PBS, anti-CD4, anti-CD8, and anti-asialo-GM1 Abs, respectively. A, Sialidase-treated cells (2 × 10^5) were injected i.p. into the depleted mice and tumor diameters were measured. B, Sialidase-treated cells (1 × 10^6) were injected i.v. into the depleted mice, and 35 d later the mice were sacrificed and lungs were weighed. C, Two days after i.p. injection of 2 × 10^5 sialidase-treated or untreated cells, 12-μm frozen sections of the injection site were stained by anti-NKp46 Alexa-647-conjugated Abs to detect NK cells and with DAPI to label cell nuclei. D, Immune synapses of activated NK cells and sialidase-treated or untreated cells were formed by merging LFA-1 in NK cells and F-actin staining. NK cells were stained by anti-CD11a Abs followed by Alexa Flour 633-conjugated goat anti-rat IgG and F-actin by Oregon green 488 phalloidin. The synapses were quantified by counting conjugates presenting polarization of LFA-1 and F-actin divided by the total number of conjugates (defined as two cells in contact). The synapses and sections containing NKP46-positive cells were examined under a Zeiss Laser Scanning Confocal Microscope (original magnification ×40). Synapses and NKP46-positive cells were counted in random fields. ***p < 0.01; **p < 0.05, versus the appropriate controls in each panel.

spleen cells for 24 h resulted in an induction of IFN-γ secretion to a level 2-fold higher than that observed in response to untreated cells (Fig. 4A). Coculturing of tumor cells treated with sialidase for 30, 45, and 60 min inversely correlated with IFN-γ production (Fig. 4B). This finding was due to a 50%, 60%, and 75% gradient of sialic acids generated on the tumor cells. NK cell depletion reduced IFN-γ concentration by 50% in cocultures of spleen cells with sialidase-treated tumor cells, as compared with similar incubation with intact spleen cells (Fig. 4C). By contrast, similar IFN-γ concentrations were observed in untreated tumor cells cocultured with either NK-depleted or intact spleen cells, indicating that the NK cells are the major source of IFN-γ production when interacting with sialidase-treated cells. Likewise, TNF-α, IL-2, IL-4, IL-6, and IL-12 were not differentially secreted in response to coculturing with sialidase-treated or untreated tumor cells (data not shown). In addition, comparison of IFN-γ levels secreted by cocultures of the immunogenic IL-1α−/− tumor cells with naive spleen cells revealed increased IFN-γ secretion to a level 10- or 5-fold higher than observed in response to untreated cells (Supplemental Fig. 3) or treated cells, respectively, as shown in Fig. 4A. Most likely, IL-1α−/− tumor cells trigger more than one immune cell populations to produce IFN-γ, whereas sialidase-treated cells mainly trigger the NK cell population.

To confirm that IFN-γ is secreted by NK cells, intracellular staining of the various cocultures was performed, whereas naive spleen cells were stained for DX5+ and CD3− to confirm expression of the NK cell marker NKP46 (Supplemental Fig. 4). As shown in Fig. 4D, IFN-γ accumulated in DX5+CD3+ cells from cultures containing sialidase-treated cells to twice the level seen in cultures containing untreated cells. Moreover, in cocultures of freshly isolated NK and sialidase-treated cells, IFN-γ accumulation increased by more than 2-fold, relative to levels in cocultures of freshly isolated NK and untreated cells (Fig. 4E).

Finally, the role of NK cells in the lysis of sialidase-treated cells was illustrated in vitro by addressing cocultures containing poly(I):poly(C) pretreated naive spleen cells and by in vivo i.v. injections of a labeled sialidase-treated and untreated cell mixture. The coculturing results revealed 32% specific lysis of sialidase-treated cells, relative to the low percentages observed in untreated cells (Fig. 4F). In vivo lysis decreased from an initial ratio of 1.0 between treated to untreated cells after injection to a ratio of 0.71 after 1 h and to a ratio of 0.23 5 h later, indicating a rapid lysis of sialidase-treated cells compared with untreated cell lysis (Fig. 4G). These results reveal that poorly sialylated tumor cells are more susceptible to NK cells than are highly sialylated tumor cells.

Sialylation is involved in the binding of NKG2D ligands and affects subsequent IFN-γ secretion and NK cell cytotoxicity.

In certain conditions, stress-induced ligands, such as NKG2D ligands, induce NK cell activation and IFN-γ secretion. Because the involvement of tumor sialylation in NKG2D engagement and IFNγ secretion had not been characterized, we initially
assessed NKG2D ligand binding to an mNKG2D fusion protein. The dependency of NKG2D engagement on sialic acid expression was illustrated by kinetic experiments. MCA-induced fibrosarcoma cells derived from WT mice were treated with sialidase for 1 h. Every 10 min during the treatment, cells were assessed for sialic acid and MHC class I levels, using SNA lectin and anti-H-2Kb Abs, respectively. Binding of the mNKG2D fusion protein increased with a decrease in SNA binding, whereas MHC class I binding to anti-H-2Kb Abs did not change during the sialidase treatment (Fig. 5A). These findings show the effect of the sialylation level on the ability of tumor NKG2D ligands to be recognized by the NKG2D receptor (Fig. 5B).

Because the increase in binding capacity of NKG2D ligands is related to the ability of NK cells to produce IFN-γ or cytotoxic activity, we were interested in assessing these phenomena as a function of different levels of tumor sialylation. Accordingly, the NKG2D receptor was blocked by pretreatment of freshly isolated NK cells with anti-NKG2D/CD134 Abs, followed by coculturing with tumor cells. Cocultures of sialidase-treated tumor cells with the blocked NK cells revealed reduced IFNγ production (by 50%), whereas a 20% reduction was observed in cocultures with untreated tumor cells, compared with the IFN-γ production attained without blocking (Fig. 5C). Lysis of sialidase-treated cells cocultured with poly(I):poly(C)-induced spleen cells was reduced by 50–80% after NKG2D blocking; however, cocultures of untreated cells grown in the same conditions showed less significant lysis reduction after blocking (Fig. 5D). Finally, the involvement of NKG2D in lysis of sialidase-treated cells was studied in vivo by i.v. injection of the cells into mice pretreated with 200 µg anti-NKG2D mAbs. Lysis of sialidase-treated cells was significantly reduced in NKG2D-treated mice, as compared with their lysis in naive mice (Fig. 5E). Thus, IFN-γ production and cell lysis are regulated by the accessibility of NKG2D ligands for binding to the NKG2D receptor. Accordingly, reduced sialic acid levels promote IFN-γ production and cell lysis by encouraging the binding of NKG2D to the receptor on NK cells.

**Discussion**

This study demonstrates that surface sialylation is an important element of the MCA-induced cancer-immunoediting process. Thus, the degree of sialylation of surface molecules is one of the parameters selected during immunoediting of the tumor cell repertoire during tumorigenesis, which shapes the intrinsic immunogeneity of the malignant cells and patterns of their interactions with the host immune system. Specifically, low levels of sialic acid on tumor cells in mice with impaired immunoediting are associated with increased interactions of the malignant cells with effector cells of the host immune system, leading to malignant cell rejection.
FIGURE 5. Sialylation is involved in the binding of NKG2D ligands and affects subsequent IFN-γ secretion and NK cell cytotoxicity. A. Four to five different MCA fibrosarcoma cell lines derived from WT mice were treated with sialidase, and binding of mNKG2D or mNCR1 fusion proteins was assessed. MCA fibrosarcoma cells derived from WT mice were treated with sialidase at 10 min intervals for 1 h to generate tumor cells bearing decreasing sialic acid levels on their surface. B. By using SNA lectin, anti-H-2K^d Abs, or fmNKG2D, the sialic acid levels (▼), MHC class I presence (▲), or NKG2D ligand levels (◼) were measured, respectively, and analyzed by flow cytometry. The binding values are presented as percentages, relative to the binding observed before sialidase treatment. C. Sialidase-treated or untreated cells were cocultured with activated NK cells or NKG2D-blocked NK cells, at a ratio of 1:1. NKG2D receptor blocking of the activated NK cells was observed by anti-NKG2D-CD134 Ab treatment; 24 h after coculturing these cells, IFN-γ secretion levels were measured in the supernatant by ELISA. D, Poly(I):poly(C) activated naïve spleen cells labeled with CFSE were cocultured with sialidase-treated or untreated cells in the presence of anti–NKG2D-CD134 Abs (○, ◊) or without these Abs (□, ▽) at different target:effector ratios. D, After 5 h incubation at 37 °C, cells were stained with 7-AAD, and specific lysis was calculated relative to the spontaneous lysis. E, Vybrant Dil-labeled sialidase-treated and Vybrant DiD-labeled untreated cells (2 × 10^5) were mixed and injected into the tail veins of naive mice or mice preinjected with 200 μg anti–NKG2D-CD34 Abs. Lungs were harvested and cells were quantified 0 and 5 h after injection using flow cytometry. The ratio of treated target cells to untreated cells was calculated. Data represent the mean ± SD of duplicate or triplicate measurements from duplicate or triplicate independent experiments. *p < 0.01; **p < 0.05, versus the appropriate controls in each panel.

In intact mice. In mice with an intact immune system, the malignant cells that arise during MCA-induced carcinogenesis are enriched with surface sialic acid residues and are not eradicated by the immune responses. These observations were obtained when using MCA fibrosarcoma cell lines derived from IL-1α−/− (18, 19) and IFN-γ−/− mice (12, 20), in which impaired immunoediting has been observed. In the case of MCA-induced fibrosarcoma cells from IL-1α−/− mice, we detected lower expression of α2-6 sialyltransferase, compared with MCA-induced lines derived from WT mice, which corroborates the results of Avidan et al. (19). Our data suggest that sialylation of the tumor cell surface or sialylation of specific moieties determines the differential ability to stimulate different immune responses. It has to be elucidated whether these observations also hold for immunoediting of epithelial tumors. Experimental approaches to assess the creation of the immunogenic repertoire during epithelial carcinogenesis are rare and complicated and have not been approached appropriately.

The less sialylated membrane-bound glycoconjugates were mimicked in this study to assess their interaction with the host immune system, using sialidase-treated nonimmunogenic cells derived from MCA-induced WT mice. The major immune cell type, which was shown to interact best with sialidase-treated tumor cells, is the NK cell. Alterations in cancer cell sialylation have been correlated previously with changes in the activity of one or more of 20 different sialyltransferases (37) in malignant cells (4). Alterations in sialylation levels of malignant cells have usually been associated with changes in invasiveness and metastasis patterns, yet seldom related to the immunogenicity of the cells or their interaction patterns with immune effector cells. Concerning sialylated tumor cell interactions with immune effector cells, it was shown, for example, that sialylated GM2 gangliosides on YAC-1 lymphoma cells inhibit in vitro interactions with cytotoxic NK cells (38). The oversialylated T- and Tn-Ags of MUC1 in breast carcinoma cells simultaneously increased IL-10 and reduced IL-12 production by dendritic cells (39). The GD3 ganglioside on tumor cells, when enriched with disialic acids, inhibits cytotoxicity of NK cells via siglec-7 (40). High levels of gangliosides secreted by tumor cells inhibit the expression of co-stimulatory molecules on dendritic cells, subsequently reducing APC-dependent T cell proliferation (41). All these reports show that sialylated molecules expressed on or secreted by the malignant cells induce immune evasion by the malignant cells and their subsequent progression. Accordingly, reduction of tumor cell sialylation levels should lead to better antitumor immune responses, as observed in this study.

In this study, we have also shown the role of sialic acids on tumor cell killing activity, contact with NK cells, and IFN-γ secretion by NK cells. Thus, depletion experiments confirmed the
involvement of NK cell-mediated in vivo growth inhibition of desialylated tumors. The increase in the number of immune syn-
apses formed between NK cells and sialidase-treated tumor cells demonstrated that their interactions are essential for lysis of malignant cells by NK cells. In addition, NK cells were shown to represent the major population that secretes augmented amounts of IFN-γ after interacting with sialidase-treated tumor cells in vitro. NK cell-derived IFN-γ may be involved in modulating innate and adaptive immune responses (42). For example, priming of Th1-biased T cell responses promotes the development of an antitumor CD8+ T cell response (43) or can activate macrophages and possibly other effector cells, leading to enhanced tumoricidal activity (44). Depletion of CD4+ or CD8+ T cells did not shift growth patterns of sialidase-treated tumor cells, whereas NK cell depletion induction progressive growth. This finding implies that NK cells rather than adaptive immune cells possibly control the initial phase of tumor growth.

NKGD2 has been shown to play a prominent role in the anti-
tumor immune response (45) by coupling the NKGD2 receptor to its ligands on tumor cells, which triggers NK cell cytolytic activity and IFN-γ secretion (46, 47). Our results show enhance-
ment of NKGD2 receptor–ligand interactions, but no alteration in the levels of MHC class I expression, upon removing sialic acids. NKGD2 receptor–ligand interactions in the sialidase-treated tumor cells were correlated to enhanced secretion of IFN-γ and in vitro or in vivo killing capacity. Moreover, blocking NKGD2 prevented the interactions with the sialidase-treated cells, thus decreasing the lysis of these tumor cells by the cytotoxic NK cells. We hypothesize that tumor cell sialylation prevents the interac-
tions of NKGD2 receptor ligands through nonspecific charge repulsion of sialic acid residues near the NKGD2 ligands (48). Another possible option for preventing ligand–receptor interac-
tions is sialylation of NKGD2 ligands (49), which have several potential glycosylation sites on their backbones (accession nos. O08602, O08603, and O08604 SwissProt database: http://www.
expasy.org/sprot/). However, O’Callaghan et al. (50) showed that NKGD2 glycosylation is not necessary for the NKGD2–REAl and NKGD2–H60 interactions. Further work is needed to demon-
strate how sialylation affects NKGD2 ligand function regarding NK cell cytotoxicity and, if so, which NKGD2 ligand is affected by sialylation and by which mechanism.

In conclusion, a high degree of tumor cell sialylation is a factor that was selected in the process of immuneediting during carci-
nogenesis. Although the direct interactions of sialic acid residues with lectin receptors, such as siglecs on NK cells, can be a negative regulator of cytolytic responses, we focused on signals activating the immune system by low sialylated tumor cells. By reducing surface sialylation, we generated more immunogenic tumor cell variants, which activated innate immune cells. By in vivo and in vitro studies, NK cells were shown to participate in growth inhibition of tumors expressing low levels of sialic acid. Fur-
thermore, NK cell activity and cytotoxicity, as well as NKGD2 ligand-receptor engagement, were shown to be dependent on the expression of tumor surface sialic acids. Finally, NKGD2 is a key receptor involved in the lysis of desialylated tumor cells. Based on these observations, we suggest that tumor sialylation plays a role in tumor immuneediting. Desialylation of malignant cells could thus serve as a future approach to induce immunogenic tumor cells in personalized medicine approaches to treat patients with cancer.

Acknowledgments
We thank Rosalyn M. White and Rona Baron from the Microbiology and Immunology Department of Ben-Gurion University for technical assistance.

Disclosures
The authors have no financial conflicts of interest.

References
1. Varki, A. 2007. Glycan-based interactions involving vertebrate sialic-acid-reco-


4. Varki, N. M., and A. Varki. 2007. Diversity in cell surface sialic acid pre-


10. Kopitz, J., C. von Reitzeinstein, M. Burchert, M. Cantu, and H. J. Gabius. 1998. Galectin-1 is a major receptor for ganglioside GM1, a product of the growth-


17. Varki, N. M., and A. Varki. 2007. Diversity in cell surface sialic acid pre-


22. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and in-


Downloaded from http://www.jimmunol.org/ by guest on November 24, 2017


